Unité des Rickettsies, CNRS UMR 6020, IFR 48, Faculté de Médecine, Marseille, France.
Proteomics Clin Appl. 2008 Apr;2(4):504-16. doi: 10.1002/prca.200780078. Epub 2008 Mar 7.
Whipple's disease (WD) is a chronic multisystemic infection, caused by the bacterium Tropheryma whipplei. The main clinical presentations are classic WD (CWD) with histologic lesions in the gastrointestinal tract, endocarditis, and isolated neurologic infection. The current strategy for diagnosis remains invasive.The present study aimed to select the protein candidates for serological diagnosis of WD. The first step was to identify candidate proteins by an immunoproteomic approach combining 2-DE using a total extract of a T. whipplei, immunoblotting, and MS. The second step was to validate the discovered biomarkers using a recombinant protein-based ELISA. Serum samples from 18 patients with WD and from 54 control individuals were tested. A sugar ABC transporter, TWT328 (sensitivity (Se) 61%, specificity (Sp) 87%, positive predictive value (PPV) 61%, negative predictive value (NPV) 87%, and positive likelihood ratio (PLR) 4.69) was the best marker for development of serodiagnosis for CWD. We also obtained a reproducible immunoreactive protein pattern for patients with isolated neurological infection due to T. whipplei (Se 100%, Sp 93%, PPV 55.5%, NPV 100%, and PLR 13.51) as an encouraging step towards noninvasive diagnosis of this particular manifestation. Nine recombinant candidates have been successfully screened with serum samples. Results from these ELISA assays skewed with those obtained with immunoblots.
惠普尔病(WD)是一种慢性全身性感染,由 Tropheryma whipplei 细菌引起。主要临床表现为经典惠普尔病(CWD),胃肠道组织学病变、心内膜炎和孤立性神经感染。目前的诊断策略仍然具有侵袭性。本研究旨在选择用于 WD 血清学诊断的蛋白质候选物。第一步是通过结合使用 T.whipplei 总提取物的 2-DE、免疫印迹和 MS 的免疫蛋白质组学方法鉴定候选蛋白。第二步是使用基于重组蛋白的 ELISA 验证发现的生物标志物。测试了 18 例 WD 患者和 54 例对照个体的血清样本。一种糖 ABC 转运蛋白 TWT328(敏感性(Se)为 61%,特异性(Sp)为 87%,阳性预测值(PPV)为 61%,阴性预测值(NPV)为 87%,阳性似然比(PLR)为 4.69)是开发 CWD 血清学诊断的最佳标志物。我们还获得了 T.whipplei 引起的孤立性神经感染患者的可重复免疫反应蛋白图谱(Se 为 100%,Sp 为 93%,PPV 为 55.5%,NPV 为 100%,PLR 为 13.51),这是朝着这种特殊表现的非侵入性诊断迈出的令人鼓舞的一步。已经成功地用血清样本筛选了 9 种重组候选物。这些 ELISA 检测结果与免疫印迹获得的结果不一致。